|1.||Driscoll, Edward M: 2 articles (07/2003 - 07/2002)|
|2.||Lucchesi, Benedict R: 2 articles (07/2003 - 07/2002)|
|3.||Hennan, James K: 2 articles (07/2003 - 07/2002)|
|4.||Willens, David E: 2 articles (07/2003 - 07/2002)|
|5.||Hong, Ting-Ting: 2 articles (07/2003 - 07/2002)|
|6.||Giboulot, Thierry: 1 article (07/2003)|
|7.||Giboulot, Thierry A: 1 article (07/2002)|
07/01/2002 - "6. The results indicate that CRL42796 is an effective in vivo antithrombotic agent against experimentally-induced carotid and coronary artery thrombosis."
07/01/2003 - "CRL42796 reduced thrombus weight in both treatment protocols. "
07/01/2003 - "A single oral dose of CRL42796 (3 mg/kg) prevented occlusive thrombosis in 4 of 6 vessels and increased time to thrombosis, albeit not significantly (right carotid artery, 134.1 minutes; left carotid artery, 145.0 minutes). "
07/01/2002 - "5. Coronary artery thrombosis was inhibited in four of five vessels treated with the lower infusion dose of CRL42796 and in five of five vessels treated with the higher infusion. "
07/01/2002 - "1. The antithrombotic effect of the glycoprotein IIb/IIIa receptor antagonist, CRL42796, was examined in canine models of carotid and coronary artery thrombosis. "
|2.||Carotid Artery Thrombosis
07/01/2003 - "This study investigates the effect of the glycoprotein IIb/IIIa receptor antagonist CRL42796 in a canine model of carotid artery thrombosis. "
07/01/2003 - "The results demonstrate that oral administration of CRL42796 prevents carotid artery thrombosis in response to deep vessel wall injury and may have potential value to be characterized in extended preclinical and clinical study."
07/01/2003 - "Prevention of carotid artery thrombosis after oral administration of the glycoprotein IIb/IIIa antagonist CRL42796."
|2.||glucuronyl glucosamine glycan sulfate (Vessel)